NOTICE OF ANNUAL GENERAL MEETING IN XINTELA AB (PUBL)

The shareholders of Xintela AB (publ) are invited to the annual general meeting on Friday, May 6 2022, at 09.00 CET at Medicon Village, Scheeletorget 1, Building 601 Lund, Sweden. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. […]

Xintela AB Year-end report January – December 2021

Summary of the year end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter October 1 – December 31, 2021Income amounted to TSEK 0 (0).Loss before tax totalled TSEK 26,643 (loss: 25,335).Loss per share* was SEK 0.30 (loss: 0.34).At December 31, 2021, the equity/assets ratio** was 16% (57). […]

Xintela granted 4.8 million SEK from Vinnova

Lund, Sweden, January 18, 2022 – Xintela has been granted SEK 4.8 million from Vinnova within the call “New and improved biological drugs in healthcare”. The grant will support a clinical phase I/IIa study to evaluate Xintela’s stem cell product XSTEM® for the treatment of patients with difficult-to-heal leg ulcers. The project, which will be […]

Xintela and ScanVet Animal Health A/S sign Letter of Intent

Xintela announces today that the company has signed a Letter of Intent with the Danish animal health company ScanVet Animal Health A/S. The parties intend to enter into an agreement to develop, market and sell EQSTEM®, Xintela’s proprietary equine stem cell product, for the treatment of joint diseases including osteoarthritis. Under the Letter of Intent, […]

Xintela AB Interim report January – September 2021

Xintela AB Interim report January – September 2021 Summary of the interim report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter July 1 – September 30, 2021 Income amounted to TSEK 0 (0). Loss before tax totalled TSEK 10,910 (loss: 8,315). Loss per share* was SEK 0.13 (loss: […]

New board of directors appointed in Targinta AB

Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstrand and Maarten de Château have been appointed as new board members. Gregory Batcheller, chairman, and Evy Lundgren-Åkerlund are already members of the board of Targinta. Gunnar Telhammar resigns as board member. The […]

Targinta selects lead drug candidate for triple-negative breast cancer

The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models. Xintela, of which Targinta is a wholly […]

Xintela Half-year Report 2021-01-01 – 2021-06-30

Summary of the half-year report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 1 April – 30 June 2021 · Income amounted to TSEK 0 (0). · Loss before tax totalled TSEK 11,797 (loss: 9,087). · Loss per share* was SEK 0.13 (loss: 0.22). · At 30 June […]